title: Prevalence of hepatitis B virus and hepatitis C virus in patients with human immunodeficiency virus infection in Central China.
abstract: Co-infection of hepatitis B virus (HBV) and/or hepatitis C virus (HCV) with human immunodeficiency virus (HIV) has an adverse effect on liver disease progression. This study investigated the prevalence of HBV and/or HCV co-infection in HIV-infected patients in Central China. A total of 978 HIV-infected patients from Hunan Province were enrolled. HBV serum markers, anti-hepatitis-C-virus antibody (anti-HCV), HBV DNA, and HBV genotypes were analyzed. The prevalence of hepatitis B surface antigen (HBsAg) and anti-HCV in HIV-infected patients was 19.4 % and 62.4 %, respectively. The prevalence of anti-HCV in HIV-positive intravenous drug users was 93.6 %. Among HBsAg-positive patients, 88.1 % were found to have at least one HBV serum marker. The rates of HIV mono-infection, HBV/HIV dual infection, HCV/HIV dual infection, and HBV/HCV/HIV triple infection were 30.4 %, 7.2 %, 50.2 %, and 12.2 %, respectively. Antibody to HBsAg (Anti-HBs) was more common in anti-HCV-positive than anti-HCV-negative patients (53.3 % vs 40.2 %, P = 0.000), but isolated hepatitis B core antibody (anti-HBc) was more common in anti-HCV-negative than anti-HCV-positive patients (24.2 % vs 12.3 %, P = 0.000). Hepatitis B e antigen (HBeAg) and sexual transmission were independent risk factors for active HBV replication. Intravenous drug use and male sex were independent risk factors, but old age and presence of HBeAg were independent protective factors for anti-HCV. Co-infection of HBV and/or HCV with HIV infection is common in central China. HCV status is associated with anti-HBs and isolated anti-HBc in co-infected patients.
authors.affiliation: Hunan Provincial Center for Diseases Control and Prevention, 450 Furongzhong Rd. sec 1, Changsha 410005, China. chenxi161@sohu.com
authors.forename: Xi
authors.initials: X
authors.lastname: Chen
authors.forename: Jian-Mei
authors.initials: JM
authors.lastname: He
authors.forename: Li-Sha
authors.initials: LS
authors.lastname: Ding
authors.forename: Guo-Qiang
authors.initials: GQ
authors.lastname: Zhang
authors.forename: Xiao-Bai
authors.initials: XB
authors.lastname: Zou
authors.forename: Jun
authors.initials: J
authors.lastname: Zheng
mesh_terms: D000328:Adult; D002681:China / Q000453:epidemiology; D060085:Coinfection / Q000453:epidemiology* / Q000821:virology; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000453:epidemiology* / Q000821:virology; D016174:Hepacivirus / Q000276:immunology; D006509:Hepatitis B / Q000150:complications / Q000453:epidemiology; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000145:classification / Q000235:genetics / Q000276:immunology*; D006526:Hepatitis C / Q000150:complications / Q000453:epidemiology / Q000276:immunology; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012307:Risk Factors; D015819:Substance Abuse, Intravenous / Q000150:complications / Q000453:epidemiology / Q000276:immunology
chemical_list: D006514:Hepatitis B Surface Antigens; D018937:Hepatitis C Antibodies